1981 trial results

Inclusion Criteria: * Type 2 Diabetes for at least 1 year. * Microalbuminuria for at least 6 months (UACR: 30-300 mg/g) * Macroalbuminuria for at least 6 months (UACR: \>300 mg/g) * HbA1c of ≤10% * Ages 18-65 years (inclusive of ages 18 and 65) * On ARBs/ACEi for at \>3months Exclusion Criteria: * Use of GLP-1 Receptor agonists or SGLT-2 inhibitors therapy in the last 3 months * History or risk for pancreatitis (e.g., history of gallstones, alcohol abuse, and hypertriglyceridemia) * Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous 3 months * Hepatic disease: Severe hepatic insufficiency and/or significant abnormal liver function defined as: 1. Aspartate aminotransferase (AST) \>3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) \>3x ULN 2. Total bilirubin \>2.0 mg/dL (34.2 µmol/L) 3. Positive serologic evidence of current infectious liver disease including Hepatitis B viral antibody IGM, Hepatitis B surface antigen and Hepatitis C virus antibody 4. Liver function tests more than 3 times the upper limit of normal * Renal impairment (serum eGFR \<30 ml/min) * HIV * Inability to give informed consent * History of gastroparesis * History of medullary thyroid carcinoma or MEN 2 syndrome * Alcoholism * Hypertriglyceridemia (\>500 mg/dl). * Any other life-threatening, non-cardiac disease * Uncontrolled hypertension (BP \> 160/100 mm of Hg) * Congestive Heart Failure class III or IV * Use of an investigational agent or therapeutic regimen within 30 days of study * Participation in any other concurrent clinical trial * Pregnant or breastfeeding patients or females of childbearing age not on 2 forms of acceptable contraceptives.